Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT)

BACKGROUND: Epistaxis is the most common symptom of hereditary hemorrhagic telangiectasia (HHT), affecting more than 98% of adults with HHT, with significant impact on quality of life. Floseal® has been shown to be effective for the management of anterior epistaxis, but has yet to be thoroughly eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, John M., Wu, Vincent, Faughnan, Marie E., Lasso, Andrea, Figol, Andrea, Kilty, Shaun J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794791/
https://www.ncbi.nlm.nih.gov/pubmed/31615556
http://dx.doi.org/10.1186/s40463-019-0379-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794791/
https://www.ncbi.nlm.nih.gov/pubmed/31615556
http://dx.doi.org/10.1186/s40463-019-0379-y

Ejemplares similares